(Il Sole 24 Ore Radiocor) - Milano, 19 mag - US biotech company Regeneron Pharmaceuticals said it had agreed to buy substantially all of the assets of genetic testing firm 23andMe for 256 million dollars following a bankruptcy auction.

Regeneron said it intended to acquire 23andMe's Personal Genome Service, Total Health and Research Services business lines, together with its Biobank and associated assets and for 23andMe to continue all consumer genome services uninterrupted.

Subject to bankruptcy court and regulatory approvals and other customary closing conditions, the transaction is expected to close in the third quarter of 2025.

"We believe we can help 23andMe deliver and build upon its mission to help those interested in learning about their own DNA and how to improve their personal health, while furthering Regeneron's efforts to use large-scale genetics research to improve the way society treats and prevents illness overall,' said Regeneron co-founder and president.

George Yancopoulos.

(RADIOCOR) 19-05-25 14:54:14 (0438) 5 NNNN